Other
Estrogen
1
Pipeline Programs↗
5
Active Trials↗
1
Companies Involved↗
Estrogen is an early-stage landscape with 1 program across 1 company. The most active players are Pfizer. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1
Analysis
Trial Status
47
clinical trials
Completed32 · 68%
Unknown status5 · 11%
Recruiting4 · 9%
Withdrawn3 · 6%
Terminated2 · 4%
Active, not recruiting1 · 2%
Clinical Trials
Trial Activity
47 trials
Cardiac Outcomes With Near-Complete Estrogen Deprivation
Recruiting·—·N/A·NCT05309655·90 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)